Large cell neuroendocrine carcinoma subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression

#3886

Introduction: Large cell neuroendocrine carcinoma (LCNEC) accounts for 1-3% of all types of lung cancer and is, similar to small-cell lung cancer (SCLC), a high-grade tumor with poor prognosis. pRb can also be used to subclassify LCNEC into SCLC-like and NSCLC-like. SCLC can be classified in 4 transcriptomic subtypes (NEUROD1high, ASCL1high, POU2F3high, YAP1high), which may have therapeutic implications. It is unclear whether these subtypes are also found in LCNEC and if they correlate with pRb expression.

Aim(s): We aimed to define LCNEC subtypes, based on immunohistochemical (IHC) expression of NEUROD1, ASCL1, POU2F3, YAP1 and pRb.

Materials and methods: Patients with resected stage I-III LCNEC, diagnosed between 2003-2012, were identified using the Netherlands Cancer and Pathology Registry and revised by 2 thoracic pathologists. Tissue microarrays were made and stained for NEUROD1, ASCL1, POU2F3, YAP1 and pRb and scored using H-scores. An H-score ≥10 was considered positive (+).

Conference:

Presenting Author: Heijboer F

Authors: Rijnsburger N, Heijboer F, Derks J, Hermans B, Hillen L,

Keywords: LCNEC, pulmonary, immunohistochemistry, pathology, pRb, transcription factors,